Deutsche Bank acknowledged positive data from AstraZeneca's tozorakimab for chronic obstructive pulmonary disease (COPD), presented at the ERS conference, supporting the drug's commercial potential. Despite this, the bank maintained a 'sell' rating on AstraZeneca shares with a target price of 11,500 pence, slightly below the current trading price. The data follows AstraZeneca's raised peak sales guidance above $5 billion, with consensus forecasts around $4 billion for 2030, suggesting room for modest upward revisions. The next key event will be analysts' reassessment of tozorakimab's revenue potential based on detailed COPD findings.
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi immunotherapy reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, extending median survival to 21.1 months from 12.7 months with Imf...
Amgen announced Phase 3 DeLLphi-305 trial results where IMDELLTRA combined with AstraZeneca's IMFINZI reduced death risk by 58% and extended median overall survival to 21.1 months in extensive-stage small cell lung cancer patients. Nearly 80% of pati...
AstraZeneca remains a strong long-term Buy due to its robust product lineup and promising pipeline, aiming for $80 billion in revenues by 2030. The company currently has 14 blockbuster drugs and expects up to 12 more from its pipeline by decade's end...
Jefferies estimates a 59% probability that AstraZeneca's kidney drug zibotentan will succeed in the phase 3 ZENITH-HP trial, with results expected in the first half of 2027. The trial tests zibotentan combined with Farxiga in patients with high prote...
Oracle and AstraZeneca have entered a collaboration to combine AstraZeneca's scientific expertise with Oracle's AI, cloud, and real-world data capabilities. The partnership aims to accelerate clinical trials by helping clinicians identify eligible pa...
